In conversation with... Stephen Strittmatter

from Listen to The Lancet Neurology · host The Lancet

Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology.

Episode metadata supplied by the publisher feed · Published Jul 20, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Stephen Strittmatter

0:00 14:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Neurology?

This episode is 14 minutes long.

When was this Listen to The Lancet Neurology episode published?

This episode was published on July 20, 2023.

Can I download this Listen to The Lancet Neurology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!